Low-Power Blue LED Modulates NF-κB and Proinflammatory Cytokines in Doxorubicin-Treated MDA-MB-231 Cells.

Area of Science:

• Oncology
• Biochemistry
• Photomedicine

Background:

• Doxorubicin is a key chemotherapy for triple-negative breast cancer (TNBC).
• High doxorubicin doses can lead to therapeutic resistance.
• A photodynamic therapeutic (PDT)-like strategy using blue LED light combined with doxorubicin has been proposed to enhance efficacy and reduce dosage.

Purpose of the Study:

• To investigate the molecular mechanisms underlying the efficacy of a PDT-like protocol in TNBC.
• To correlate the expression of inflammatory markers (NF-κB, IL-8, IL-6, IL-1β) with TNBC cell survival under the PDT-like treatment.

Main Methods:

• Utilized MDA-MB-231 TNBC cells.
• Administered doxorubicin treatment followed by irradiation with a blue LED device.
• Quantified the expression of NF-κB/p65 nuclear levels.
• Measured mRNA levels of IL-6, IL-1β, and IL-8.

Main Results:

• The PDT-like protocol enhanced NF-κB/p65 nuclear levels in doxorubicin-treated MDA-MB-231 cells.
• IL-6 mRNA levels were significantly increased by the PDT-like strategy.
• IL-1β and IL-8 mRNA were upregulated by doxorubicin, irrespective of blue LED irradiation.

Conclusions:

• The PDT-like protocol effectively elevates inflammatory signals, including NF-κB and IL-6.
• Understanding these inflammatory pathways provides insights into the mechanism of this novel therapeutic approach for TNBC.
• This strategy holds promise for overcoming doxorubicin resistance in TNBC treatment.